Dr Kenneth Savin, Redwire | Groundbreaking ISS Biotech Discoveries

This episode features our conversation with Dr Kenneth A. Savin, Chief Scientist at Redwire. Dr. Savin was named to TIME’s “2025 TIME100 Health List of the 100 Most Influential People in Global Health.” We discuss his 20-plus year career and expertise in the pharmaceutical industry and his pioneering work accelerating cutting-edge space biotech research capabilities, leveraging microgravity to improve human health on Earth. At Redwire, Dr. Savin has overseen trailblazing investigations onboard the International Space Station (ISS) in partnership with NASA and the ISS National Laboratory. Redwire successfully bioprinted the first human knee meniscus and first live human cardiac tissue using its BioFabrication Facility on the ISS. These breakthroughs address challenges faced by millions of people worldwide through the application of organ transplantation and tissue therapy and advance the next generation of pharmaceutical therapies. Dr. Savin has coordinated groundbreaking protein crystallization investigations onboard the ISS with pharmaceutical companies like Eli Lilly and Company (Lilly) and Bristol Myers Squibb using Redwire’s in-space pharmaceutical lab, PIL-BOX, for improved drug development. These investigations have focused on various applications to address the world’s most prevalent conditions, including antiviral, antifungal, and antiseizure applications, heart disease, and bone loss. Hosted by Bobby Gordon. This episode was recorded on December 2, 2024, and information presented in this episode is current as of this date.